US/UK/Canada

Share

Pick a time period -
Tags ( Active)

BioStock: The future of obesity treatment - Iconovo develops intranasal semaglutide

Iconovo has initiated the development of an intranasally inhaled and reformulated version of semaglutide to treat obesity. By utilizing its inhalation-driven intranasal device, ICOone Nasal, the company aims to create a more user-friendly treatment than current semaglutide injections. The goal is to achieve preclinical proof-of-concept and enter into a licensing agreement, according to CEO Johan Wäborg in an interview with BioStock.Read the full article at biostock.se : https://www.biostock.se/en/2024/09/the-future-of-obesity-treatment-iconovo-develops-

BioStock: Iconovo initiates development of inhaled obesity treatment

Iconovo has filed a broad patent application for inhaled GLP-1 receptor agonists, used for the treatment of obesity and type 2 diabetes. This is a rapidly growing market, and Iconovo aims to introduce a more patient-friendly alternative to today’s injections.– This marks the first step in Iconovo’s new initiative to develop more convenient, reliable, and cost-effective treatments for obesity, the company stated.Read the full article at biostock.se : https://www.biostock.se/en/2024/05/iconovo-initiates-development-of-inhaled-obesity-treatment/ This is a

BioStock: Busy days for Iconovo at BIO-Europe

Iconovo had three hectic days at BIO-Europe, with a large number of meetings booked with potential partners. The company especially highlighted their latest innovation, ICOone Nasal, enabling inhalation through the nasal cavities. BioStock reached out to Fredrik Radencrantz, the company’s Director Business Development, to find out more.Read the full article at biostock.se: https://www.biostock.se/en/2023/11/busy-days-for-iconovo-at-bio-europe/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

BioStock: Iconovo welcomes Gerald Engström as largest shareholder through share issue

Iconovo carries out a directed share issue that provides the company with approximately 19.2 MSEK. The issue is directed to a number of existing shareholders, including Gerald Engström who has chosen to invest 12.5 MSEK, making him the largest shareholder in the company. This not only strengthens the ownership structure but also creates the necessary conditions for working strategically towards the long-term goals.Read the full article at biostock.se: https://www.biostock.se/en/2023/10/iconovo-welcomes-gerald-engstrom-as-largest-shareholder-through-share-issue/ This is a press release

BioStock Investor Meeting: Iconovo

Iconovo presented at BioStock Investor Meeting, September 20. The event took place in Stockholm, featuring several exciting life science companies presenting their business cases to investors and potential partners.See the presentation via: BioStock Investor Meeting September 2023 | Iconovo - YouTube  See the interview via:  BioStock Investor Meeting | Interview with Iconovo | September 2023 - YouTube  This is a press release from BioStock - Connecting Innovation & Capital. https://www.

BioStock: Iconovo makes progress in the outlicensing process for ICOpre

Iconovo is approaching the out-licensing of the inhaler ICOpre by now actively seeking contact with potential partners. The company is collaborating with investment bank Stifel to maximise business value and several international pharmaceutical companies have already expressed interest through confidential disclosure agreements.Read the full article at biostock.se: https://www.biostock.se/en/2023/09/iconovo-makes-progress-in-the-outlicensing-process-for-icopre/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

BioStock: Iconovo on the way to profitability

Iconovo, a leading developer of inhalation products, consolidates its financial targets for 2027 – revenues of 250 MSEK with an EBIDTA margin of 50 percent. Approximately 85 percent of the revenue is expected to come from projects that have already been initiated. In addition, the company expects to achieve profitability during one quarter as early as next year and 2025, as well as full-year profitability in 2026. BioStock contacted CEO Johan Wäborg to gain a deeper understanding of the company’s goals.Read the full article at biostock.se: https://www.biostock.se/en/2023/08/iconovo-on-

BioStock: Iconovo initiates collaboration with Affilogic

Iconovo has recently entered into several collaboration agreements, the latest of which with the French biotech company Affilogic. The collaboration concerns a feasibility study with inhalable affinity proteins, so-called Nanofitins, based on Iconovo’s disposable inhaler ICOone. After the study is completed, there are good opportunities to expand the collaboration, according to the company. The goal of the project is to develop a new treatment for lung diseases.Read the full article at biostock.se: https://www.biostock.se/en/2023/06/iconovo-initiates-collaboration-with-affilogic/ This

BioStock: Iconovo launch Accelerator Program

Iconovo has chosen to launch an Accelerator Program to facilitate the opportunities for the company’s customers to obtain EU funding for the development of novel pharmaceuticals. The programme is made possible through a collaboration with the consulting company Argentum, which specialises in structuring and managing application processes for EU funding. BioStock contacted Måns Österberg, Director Alliance Management at Iconovo, to learn more about the initiative.Read the full article at biostock.se: https://www.biostock.se/en/2023/06/iconovo-launch-accelerator-program/ This is a press

BioStock: Iconovo initiates structured sales process for ICOpre

Iconovo is currently in negotiations with global pharmaceutical companies regarding the company's latest developed inhaler platform, ICOpre. The company has engaged the global investment bank Stifel to maximize the value and structure the outlicensing process. BioStock contacted Iconovo's CEO Johan Wäborg to find out more.Read the full article at biostock.se: https://www.biostock.se/en/2023/05/iconovo-initiates-structured-sales-process/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

BioStock: Iconovo’s oxytocin treatment in clinical phase I study

Postpartum haemorrhage is the leading cause of maternal mortality globally, especially in developing countries. Monash University is collaborating with Iconovo to develop an inhalable, preventive oxytocin treatment that aims to provide effective protection against these bleedings. Iconovo was recently able to announce that Monash has started a clinical phase I study with the treatment in Melbourne. In addition, the product is featured in Designing Motherhood, an international design exhibition. Måns Österberg at Iconovo tells us more about the project.Read the full article at biostock.se:

BioStock: Arcede Pharma and Iconovo receive funding from Swelife

Arcede Pharma, Iconovo and Lund University has received just over 2 MSEK from Swelife for the development of the inhaled treatment RCD405 for COPD and severe asthma. The grant will be used to develop an inhalation product for use in clinical studies and continue to study the candidate’s dual mechanism of action.Read the full article at biostock.se: https://www.biostock.se/en/2023/04/arcede-pharma-and-iconovo-receive-funding-from-swelife/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

BioStock: Iconovo carries out directed share issue for continued value creation

Recently, Iconovo carried out a directed share issue that strengthened the cash position by 55 MSEK, enabling continued value creation in 2023. The capital injection will be used to negotiate an agreement for the company’s most recently developed inhaler ICOpre, as well as move the ICOcap project forward and establish the subsidiary Iconovo Pharma. Iconovo also plans to leverage the opportunity within nasal inhalation after seeing positive results for ICOone Nasal in the pandemic project with the Bill & Melinda Gates Foundation.Read the full article at biostock.se: https://www.biostock.

BioStock: Iconovo starts 2023 with negotiations for ICOpre

Iconovo enters the new year with confidence after a rewarding and eventful 2022. During the year, the company moved into new facilities at Ideon Science Park, strengthened the patent portfolio, entered into collaboration with Galenica and initiated a pandemic project together with the Bill & Melinda Gates Foundation. In addition, Iconovo recently entered negotiations with a potential licensing partner for the company’s inhaler ICOpre. CEO Johan Wäborg talks more about the negotiations and possibilities in 2023 in an interview with BioStock.Read the full article at biostock.se: https://

BioStock: Iconovo establishes Nordic pharmaceutical sales

Iconovo has started building up the subsidiary Iconovo Pharma, which will sell and market pharmaceuticals in the Nordic region. Inhalation products are a natural focus area for Iconovo Pharma, but they may also consider including other products if both the product and business model are attractive. The portfolio will consist of in-licensed, complex generic products and proprietary inhalation products. The first proprietary product in the portfolio is expected to be a generic equivalent of AstraZeneca’s blockbuster Symbicort Turbuhaler. BioStock contacted Fredrik Radencrantz, Director Business

BioStock: Iconovo reports Q3 and arranges pandemic event

Iconovo recently published its report for the third quarter where they reported on progress within the projects and an increased sales compared to the same period last year. In October, the company arranged a network meeting at Medicon Village in Lund regarding the importance of preparing for the next pandemic. During the event, Iconovo talked about the project with the Bill & Melinda Gates Foundation for the development of a low-cost product for viral infections based on ICOone Nasal, the company's nasal disposable inhaler that recently received good reviews in a user study.Read the full

BioStock: Founder and CTO on Iconovo’s journey

The inhalation company Iconovo was founded in 2013 by several people with extensive experience in the development and commercialization of inhalation drugs. Today, the company has four patent-protected inhalation platforms, nine development agreements with international pharma companies and over 30 employees. BioStock interviewed Orest Lastow, co-founder and CTO, about Iconovo’s journey from the start to now.Read the full article at biostock.se:https://www.biostock.se/en/2022/10/founder-and-cto-on-iconovos-journey/ This is a press release from BioStock - Connecting Innovation & Capital.

BioStock: Iconovo looks to the US where it now meets quality requirements

One of Iconovo’s goals is to launch future inhalation products in the US, the world’s largest pharmaceutical market. The company has several products in the pipeline directed towards this ambition, including the generic versions of GSK’s Ellipta portfolio in ICOpre and AstraZeneca’s Symbicort in ICOres. There are also significant opportunities in the US for the development projects in the business area that Iconovo calls innovative inhalation products. On Monday, the news came that the company’s quality system (QMS) meets the requirements set by the FDA’s Quality System Regulation, which is a

BioStock: Iconovo’s partner explores opportunities in Bangladesh

Together with ISR, Iconovo is developing an inhaled Covid-19 vaccine in ICOone and a nasal version in ICOone Nasal. ISR has now signed a MoU agreement with the CRO Bangladesh Clinical Trials for a clinical phase I study with the vaccine, as well as with UniMed UniHealth Pharmaceuticals for manufacturing and distribution in Bangladesh. However, these agreements are only declarations of intent, not binding agreements, but they are nevertheless good news for Iconovo as it means significant progress within the vaccine project.Read the full article at biostock.se: https://www.biostock.se/en/

BioStock: Iconovo receives order for nasal Covid-19 vaccine development

Earlier this year, two Swedish life science companies, Iconovo, which develops complete inhalation products, and ISR, which develops immunotherapies, came together to start working on an inhalable Covid-19 vaccine using Iconovo’s ICOone platform. Now, the two companies have announced another agreement, this time for developing a nasal application of the vaccine using Iconovo’s new version of ICOone, called ICOone Nasal. The new application will lead to a faster track through clinical studies and thus a quicker path to market for this much-needed therapy.Read the full article at biostock.se:

BioStock: Iconovo participates in vaccine race

All Covid-19 vaccines on the market are given in injection form by healthcare professionals and require transport and storage at low temperatures. Inhalation company Iconovo and immunotherapy company ISR want to change this by developing an inhaled Covid-19 vaccine that can be stored at room temperature and is easily administered by the patients themselves with Iconovo's disposable inhaler ICOone. The inhaled vaccine reaches the affected area of the lungs directly, which is expected to create a protective effect against the virus.Read the full article at biostock.se: https://www.biostock.

BioStock: Iconovo's CEO comments on the capital raise

Last week Iconovo carried out a directed share issue of 75 MSEK at a subscription price of 70 SEK per share. A large part of the proceeds from the issue will be used to expand the project portfolio in the field of innovative inhalation products and to build up the Nordic sales of pharmaceuticals through the pharmaceutical division Iconovo Pharma. BioStock contacted Iconovo’s CEO Johan Wäborg to find out more about which doors are opened thanks to the directed share issue.Read the full article at biostock.se: https://www.biostock.se/en/iconovos-ceo-comments-on-the-capital-raise/This is a

BioStock: Iconovo's high aiming business goals

Last week, Iconovo announced its financial targets for 2026. In five years, the company expects to have ten projects in development and five launched inhalation products that generate royalties. In addition, the goal is to enter into 1 – 3 new customer agreements per year on the way there. All in all, this is expected to generate sales of 200 million SEK and an operating profit of 100 million SEK in 2026. Iconovo also sees two potential upsides: royalty revenue from innovative inhalation products as well as from royalty revenue from generic Symbicort in the US.Read the full article at

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe